261203: A Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemo

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/168/31/50

Funding

  • Baxalta Innovations GmbH
  • Baxalta Innovations GmbH